Outcome of Treatment for Congenital Toxoplasmosis, 1981-2004: The National Collaborative Chicago-Based, Congenital Toxoplasmosis Study

• DOI: 10.1086/501360
• Publication Date: 2006-04-18T17:58:54Z
• Authors: R. McLeod; K. Boyer; T. Karrison; K. Kasza; C. Swisher; N. Roizen; J. Jalbrzikowski; J. Remington; P. Heydemann; A. G. Noble; M. Mets; E. Holfels; S. Withers; P. Latkany; P. Meier
• Keywords: Toxoplasmosis; Chorioretinitis

Without treatment, congenital toxoplasmosis has recurrent, recrudescent, adverse outcomes. Long-term follow-up of infants with treated throughout their first year life pyrimethamine and sulfadiazine not been reported.Between 1981 2004, one hundred twenty (current mean age +/- standard deviation, 10.5 4.8 years) were 1 2 doses plus sulfadiazine; therapy was initiated shortly after birth continued for 12 months. Children who received treatment evaluated at predetermined intervals; the focus evaluations on prespecified end points: motor abnormalities, cognitive outcome, vision impairment, formation new eye lesions, hearing loss.Treatment without substantial neurologic disease resulted in normal cognitive, neurologic, auditory outcomes all patients. Treatment had moderate or severe (as defined this article Treatments subsection Methods) and/or >72% patients, none sensorineural loss. Ninety-one percent children 64% those did develop lesions. Almost these are markedly better than reported untreated month earlier decades (P<.01 to P<.001). Sex severity comparable our groups, no significant differences efficacy toxicity noted between groups (P > .05).Although well favorable we indicate importance diagnosis toxoplasmosis.